Wow, the US Patent Office sure is bending over backwards for RGRX lately. ANOTHER U.S. Patent was granted TODAY (23rd). It is 8,426,365 number. It is for TB 4 in congestive heart failure. Of interest is that is was reviewed by the #$%$ lady who for 8 years has been always been rejecting RGRX over piddling details. RGRX is now well covered for TB 4 in heart. But not sure it will help, or if Finkelstein will ever disclose this to investors. But this board finds out and discloses FIRST. Not sure it's enough to bring in a partner tho'. But it helps that a big pharma at least knows that RGRX has a lock on TB 4 in heart now.
Been investing for many years, and never, never have seen a CEO so "un-inclined" - - "disinterested"
in presenting news that might support or lift the price of the shares for which he is the primary care-giver.
But I guess at $50 an hr, he cannot do everything: open the mail, answer the phone, turn off the lights and lock the door each nite, etc, etc. - - - or perhaps the BOD has not entrusted him with any PR responsibility (due to lack of confidence in his ability to communicate factually ? ? ? )
But his resignation would give a real boost to the share price - - - and perhaps even bring aboard one of those collaborators, who might feel more inclined if they did not have to deal with him,.
still lighting candles, but the beads are wearing thin.